Insight Molecular Diagnostics Inc. (IMDX) — Cash Flow-to-Debt Ratio
Insight Molecular Diagnostics Inc. (IMDX) has a Cash Flow-to-Debt Ratio of -0.08x as of September 2025, meaning its operating cash flow of $-4.50 Million could theoretically repay 0% of its total liabilities ($53.13 Million) in one year. See Insight Molecular Diagnostics Inc. free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Insight Molecular Diagnostics Inc. Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Insight Molecular Diagnostics Inc. across 12 annual periods. Also explore net asset momentum of Insight Molecular Diagnostics Inc. to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Insight Molecular Diagnostics Inc. (2013–2024)
Year-by-year debt coverage analysis for Insight Molecular Diagnostics Inc.. For market capitalisation and broader financial context, see Insight Molecular Diagnostics Inc. market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.44x | $-20.71 Million | $47.35 Million | ▼ -2.1% |
| 2023 | -0.43x | $-23.32 Million | $54.42 Million | ▲ +43.1% |
| 2022 | -0.75x | $-45.57 Million | $60.50 Million | ▼ -97.7% |
| 2021 | -0.38x | $-35.94 Million | $94.35 Million | ▲ +67.8% |
| 2020 | -1.18x | $-25.98 Million | $21.94 Million | ▲ +45.8% |
| 2019 | -2.19x | $-19.71 Million | $9.02 Million | ▼ -14.3% |
| 2018 | -1.91x | $-11.65 Million | $6.09 Million | ▲ +17.0% |
| 2017 | -2.30x | $-13.38 Million | $5.81 Million | ▼ -40.4% |
| 2016 | -1.64x | $-7.52 Million | $4.58 Million | ▲ +10.2% |
| 2015 | -1.83x | $-4.23 Million | $2.31 Million | ▼ -1066.6% |
| 2014 | -0.16x | $-1.16 Million | $7.43 Million | ▼ -3.1% |
| 2013 | -0.15x | $-710.00K | $4.67 Million | — |